首页|瑞舒伐他汀钙联合氢氯吡格雷对冠心病患者介入治疗结局及炎症指标的影响

瑞舒伐他汀钙联合氢氯吡格雷对冠心病患者介入治疗结局及炎症指标的影响

扫码查看
目的 分析瑞舒伐他汀钙联合氢氯吡格雷对冠心病患者介入治疗结局及炎症指标的影响.方法 选取2020年 1 月至 2022 年 12 月我院收治的 80例采用介入术治疗的冠心病患者作为研究对象,按照治疗方案差异将其分为单药组(40 例,氢氯吡格雷治疗)和联合组(40 例,瑞舒伐他汀钙联合氢氯吡格雷治疗).比较两组的治疗效果.结果 联合组的治疗总有效率显著高于单药组(P<0.05).治疗后,联合组的C反应蛋白(CRP)、降钙素原(PCT)、可溶性CD40配体(sCD40L)水平均显著低于单药组,胰岛素样生长因子-1(IGF-1)水平显著高于单药组(P<0.05).治疗后,联合组的QT离散度、QRS波时限、室性期前收缩、短阵室性心动过速均显著低于单药组,窦性心律R-R间期标准差及相邻窦性心律R-R间期平均值均显著高于单药组(P<0.05).两组的不良反应总发生率比较,差异无统计学意义(P>0.05).联合组的心脑血管不良事件发生率低于单药组(P<0.05).结论 瑞舒伐他汀钙联合氢氯吡格雷可改善冠心病患者介入治疗结局,并快速消除患者炎症应激反应.
Effects of rosuvastatin calcium combined with hydroclopidogrel on the outcome and inflammatory indexes of interventional therapy in patients with coronary heart disease
Objective To analyze the effects of rosuvastatin calcium combined with hydroclopidogrel on the outcome and inflammatory indexes of interventional therapy in patients with coronary heart disease.Methods A total of 80 patients with coronary heart disease treated by interventional therapy in our hospital from January 2020 to December 2022 were selected as the research objects.According to the difference of treatment plan,the patients were divided into single drug group(40 cases,hydroclopidogrel treatment)and combined group(40 cases,rosuvastatin calcium combined with hydroclopidogrel treatment).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the combined group was significantly higher than that in the single drug group(P<0.05).After treatment,the levels of C-reactive protein(CRP),procalcitonin(PCT)and soluble CD40 ligand(sCD40L)in the combined group were significantly lower than those in the single drug group,and the level of insulin-like growth factor-1(IGF-1)was significantly higher than that in the single drug group(P<0.05).After treatment,the QT dispersion,QRS wave duration,ventricular premature contraction and short ventricular tachycardia in the combined group were significantly lower than those in the single drug group,and the standard deviation of sinus rhythm R-R interval and the average value of adjacent sinus rhythm R-R interval were significantly higher than those in the single drug group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The incidence of cardiovascular and cerebrovascular adverse events in the combined group was lower than that in the single drug group(P<0.05).Conclusion Rosuvastatin calcium combined with hydroclopidogrel can improve the outcome of interventional therapy in patients with coronary heart disease and quickly eliminate the inflammatory stress response.

coronary heart diseaseinterventional therapyrosuvastatin calciumhydroclopidogrel

李玥、周杰

展开 >

宝鸡市陈仓医院心血管内科,陕西 宝鸡,721300

冠心病 介入治疗 瑞舒伐他汀钙 氢氯吡格雷

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(2)
  • 13